این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Middle East Journal of Cancer، جلد ۱۳، شماره ۴، صفحات ۶۱۶-۶۲۳
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Immune Checkpoint Inhibitors-induced Thyroid Dysfunction in Patients with Advanced Malignancies
چکیده انگلیسی مقاله Background: Immune checkpoint inhibitors (ICIs), including antiprogrammed cell death receptor-1, antiprogrammed cell death ligand-1, and anticytotoxic T-lymphocyte-antigen 4, have improved patients’ outcome in advanced malignancies. These agents are associated with immune-related adverse events, including skin toxicity, gastrointestinal toxicity, hepatotoxicity, renal toxicities, and endocrinopathies.Method: We retrospectively reviewed the electronic medical records of patients treated with ICIs for advanced malignancies from two tertiary cancer care centers in the Emirate of Dubai, United Arab Emirates (UAE), including Dubai Hospital and American Hospital from November 2015 to January 2019. The patients were identified through the hospital cancer registry. We retrospectively collected data regarding the subjects’ demographics, cancer type, type of ICIs, thyroid-related adverse events, and duration of treatment.Results: In the present paper, 43 patients received ICI and 19 (44%) developed thyroid dysfunctions. The median age of ICI-receiving subjects was 60 (27-80) years; 26 of them were male and 17 were female. Pembrolizumab was the most used agent (42%). Pretreatment thyroid functions were normal for all the patients. Following treatment initiation, 19 (44%) patients developed thyroid abnormalities, including overt hypothyroidism (n = 11, 57%), overt hyperthyroidism (n = 2, 11%), subclinical hypothyroidism (n = 4, 21%), and subclinical hyperthyroidism (n = 2, 11%). Thyroid abnormalities developed in 56% of them treated with Pembrolizumab and 37% treated with Nivolumab.Conclusion: Hypothyroidism was the most prevalent thyroid adverse event in the patients treated with ICIs in our study and the majority of thyroid dysfunction encounters took place in the first 6 weeks after ICI initiation. The treatment was well tolerated and there were no treatment-related discontinuations or deaths.
کلیدواژه‌های انگلیسی مقاله immunotherapy, Hypothyroidism, Malignancy
نویسندگان مقاله Muhammad Farooq Latif |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Elamin Abdelgadir |
Endocrinology Department, Dubai Hospital, Dubai, UAE

Mohamed Omara |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Fauzia Rashid |
Endocrinology Department, Dubai Hospital, Dubai, UAE

Syed H Tirmazy |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Faraz Khan |
Medical Oncology Department, American Hospital, Dubai, UAE

Maroun El Khoury |
Medical Oncology Department, American Hospital, Dubai, UAE

Alaaeldin Bashier |
Endocrinology Department, Dubai Hospital, Dubai, UAE

Fatheya Alawadi |
Endocrinology Department, Dubai Hospital, Dubai, UAE

Kaltar Das |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Susheel Kumar |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Abdul Q Basit |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Dalia El-Shourbagy |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Dina Hamza |
Medical Oncology Department, Dubai Hospital, Dubai, UAE

Faisal Azam |
Medical Oncology Department, King Fahad Specialist Hospital Dammam, Saudi Arabia

نشانی اینترنتی https://mejc.sums.ac.ir/article_48393_a064949aa8ea057da78e2d4db08ca2d6.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات